FDA Accepts Amended Protocol for Phase 3 Trial of Buntanetap in Alzheimer Disease

Published Date: 12 Jan 2025

The revised protocol merges the 6-month symptomatic and 18-month disease-modifying studies into a single trial with a 6-month symptomatic readout and a 12-month disease-modifying evaluation.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot